NCT00430625View on ClinicalTrials.gov

A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 15, 2007

Primary Completion Date

April 1, 2009

Study Completion Date

April 1, 2009

Conditions
Gaucher Disease, Type 1
Interventions
BIOLOGICAL

VPRIV ®,

Intravenous (IV) infusion, every other week via intravenous infusion for 12 months

Trial Locations (5)

Unknown

Hipolito Yrigoyen, Buenos Aires

Shaare Zedek Medical Center, Jerusalem

Sociedad Espanola de Socorros Mutuos, Asunción

National Research Center for Haematology, Moscow

La Rabta Hospital, Tunis

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY